文献速递造血干细胞移植与细胞治疗淋巴瘤白血病

移植物抗宿主病预防方案对异基因造血干细胞移植后第二原发恶性肿瘤的影响

Impact of graft-versus-host disease prophylaxis on second primary malignancies after allogeneic haematopoietic stem cell transplantation.
PubMed 文献 · Br J Haematol · 2025-07-19

该研究评估抗胸腺细胞球蛋白(ATG)联合移植后环磷酰胺(PTCy)对比其他移植物抗宿主病(GvHD)预防方案对第二原发恶性肿瘤(SPM)发生率的影响。1418例可评估患者中138例发生SPM,5年累积发生率10.6%(95%CI:9-13)。ATG-PTCy使用与SPM风险降低独立相关(HR 0.65,p=0.02),而较高年龄(HR 1.10,p=0.03)和中重度慢性GvHD(HR 1.54,p=0.02)与SPM风险增加相关。

要点

  • ATG-PTCy方案与SPM风险降低独立相关(HR 0.65,p=0.02)。
  • 中重度慢性GvHD与SPM风险增加相关(HR 1.54,p=0.02)。
  • 移植受者发生恶性肿瘤的风险为一般人群的2.45倍(p<0.01)。

核心结论

  • ATG-PTCy似乎可降低异基因造血干细胞移植后SPM风险。
  • 移植幸存者的SPM主动监测和筛查对确保良好结局至关重要。

研究设计与样本

  • 研究纳入1418例可评估的异基因造血干细胞移植患者,中位随访6125人年。
  • 研究评估ATG联合PTCy对比其他GvHD预防方案对SPM发生率的影响。

主要发现

  • 138例患者发生SPM,5年累积发生率为10.6%(95%CI:9-13)。
  • ATG-PTCy使用与SPM风险降低独立相关(HR 0.65,p=0.02)。
  • 较高年龄与SPM风险增加相关(HR 1.10,p=0.03),中重度慢性GvHD与SPM风险增加相关(HR 1.54,p=0.02)。
  • 与一般人群相比,HSCT受者发生恶性肿瘤的可能性为2.45倍(p<0.01)。
  • 自SPM诊断起的3年总生存率为69.8%(95%CI:61-77),血液系统SPM与较差生存独立相关(HR 2.40,95%CI:1.3-4.5,p<0.01)。

临床怎么用

  • 作者认为ATG-PTCy似乎可降低HSCT后SPM风险。
  • 作者建议对移植幸存者进行SPM的主动监测和筛查。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Second primary malignancies (SPMs) are a well-recognized late complication of allogeneic haematopoietic stem cell transplantation (HSCT). This study aims to evaluate the impact of anti-thymocyte globulin (ATG) and post-transplant cyclophosphamide (PTCy) combination on the incidence of SPMs, compared to other graft-versus-host disease (GvHD) prophylactic regimens. Among 1418 evaluable patients with a median follow-up of 6125 person-years, 138 patients developed an SPM. The cumulative incidence at 5 years was 10.6% (95% CI: 9-13). The use of ATG-PTCy was independently associated with a reduced risk of developing SPM (Hazard Ratio [HR], 0.65; p = 0.02), while older patient age (HR, 1.10; p = 0.03) and moderate-to-severe chronic GvHD (HR, 1.54; p = 0.02) were associated with an increased risk of SPM. Compared to the general population, HSCT recipients were 2.45 times more likely to develop a malignancy (p < 0.01). The 3-year overall survival from the time of SPM diagnosis was 69.8% (95% CI: 61-77) with haematological SPM independently associated with inferior survival (HR: 2.40; 95% CI: 1.3-4.5; p < 0.01). Fifteen patients (11%) developed more than one SPM. In conclusion, ATG-PTCy appears to reduce the risk of SPM post-HSCT. Active surveillance and screening for SPMs in transplant survivors are of paramount importance to ensure favourable outcomes.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Desai N, Al-Shaibani E, Alfaro-Moya T, et al. Impact of graft-versus-host disease prophylaxis on second primary malignancies after allogeneic haematopoietic stem cell transplantation. Br J Haematol. 2025. PMID: 40682490. doi:10.1111/bjh.70006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。